Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study Summary A Turkish Oncology Group study investigated the prognostic and Read More
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway Summary Blocking the IL-33/IL1RL1 pathway presents a promising dual approach for cancer therapy. IL-33, released by stressed or Read More
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B Summary The DisTinGuish trial Part B investigated the combination of DKN-01, a DKK1 inhibitor, and tislelizumab, an anti-PD-1 antibody, as Read More
Metabolic alterations driven by LDHA in CD8 + T cells promote immune evasion and therapy resistance in NSCLC Summary Lung cancer cells often evade the immune system by manipulating CD8+ T cells, the body’s primary Read More
Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs Summary Delivering plasmids encoding IL-12 and CD40L (CD154) directly into tumors can effectively trigger antitumor immunity. Read More
Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study Summary This study investigated the effectiveness of combining transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), targeted therapy, Read More
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma Summary Real-world data on idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy for multiple Read More
Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction Summary Researchers developed a novel immunotherapeutic strategy that reprograms the IL-18 pathway to combat refractory malignancies in mice. By engineering a “decoy” Read More
A ferritin-targeted biohybrid triggering ferroptosis immunotherapy via activating endogenous iron and replenishing exogenous iron simultaneously Summary This research introduces a novel biohybrid nanoparticle that combats cancer by triggering ferroptosis and enhancing immunotherapy. The nanoparticles target Read More
Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy Summary Human Fas ligand (CD95L) is a key player in immune cell-mediated killing of cancer cells. However, cancer cells can Read More
1 Million+ Views and Counting..!
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
